An IL-2 Receptor Targeted Toxin with Reduced VLS

Award Information

Agency: Department of Health and Human Services	Branch: N/A	Award ID: 75956	Program Year/Program: 2005 / SBIR
Agency Tracking Number: AI063910	Solicitation Year: N/A	Solicitation Topic Code: N/A	Solicitation Number: N/A

Small Business Information: ANJIN GROUP, INC.
10 CHILHOWIE CT. COCKEYSVILLE, MD 21030 2202
View profile »

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No

Phase 1: Fiscal Year: 2005

Title: An IL-2 Receptor Targeted Toxin with Reduced VLS

Agency: HHS

Contract: 1R43AI063910-01

Award Amount: $144,786.00

Abstract:
DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of refractory cutaneous T cell lymphoma. The fusion protein toxin technology has not been widely developed due adverse events, especially vascular leak syndrome (VLS), associated with administration of these agents. The Anjin Group Inc [AGI] proposes to develop a third generation diphtheria toxin-based platform, modified to reduce VLS. Fusion protein toxins developed from such a toxophore may have broader clinical application due to an altered risk benefit profile for patients including those with non-life threatening disease.

Principal Investigator:
Johanna C. Vanderspek
4105611434
ANJIN_GROUP@EARTHLINK.NET

Business Contact:

5088316383

Small Business Information at Submission:

Anjin Group, Inc.
10 Chilhowie Ct. Cockeysville, MD 21030

EIN/Tax ID: 020669751

DUNS: N/A

Number of Employees: N/A

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No